Roche joins drugmakers expecting China growth; FDA reviews safety of HIV drug combo;

  @FiercePharma:  Avastin fails stomach-cancer trial. Article | Follow @FiercePharma

> Roche expects sales of drugs in China to account for about half of its pharmaceutical revenue from the Asia-Pacific region within three years, spurred by higher incomes and the nation's health reforms. Report

> FDA announced it was reviewing clinical data that suggest the HIV drug Invirase, which is marketed by Roche's Genentech unit, could cause heart problems when given in combination with Abbott Laboratories' Norvir. Report

> Generics maker Watson Pharmaceuticals said its fourth quarter earnings rose slightly to $56.9 million on revenues of $786 million. Report

> Forest Laboratories said the FDA denied approval of its drug Bystolic as a treatment for stable chronic heart failure. Report

> Health Canada approved the use of Merck's Gardasil vaccine to protect boys and young men against the human papillomavirus and genital warts. Report

> Roche's blockbuster cancer drug Xeloda received a European Union recommendation for a treatment of early colon cancer. Report

Biotech News

 @FierceBiotech: Pharma giants Lilly, Merck and Pfizer are joining forces behind Asian cancer research group. Article | Follow @FierceBiotech

 @JohnCFierce: Call me crazy, but in a Termeer/Icahn showdown, I'm giving the edge to Termeer.  Follow @JohnCFierce 

> The FDA has approved Pfizer's childhood vaccine Prevnar-13, which significantly expands the protection provided by Prevnar 7, a global blockbuster with $3 billion in annual sales. Article

> Few industries were as keen to see a new healthcare reform bill pass as BIO, which had carefully shepherded a provision providing 12 years of data exclusivity for biologics through a gauntlet of consumer advocates who would have gleefully cut that span down to five years. Story

> Shares of Salix reversed course in after-market trading yesterday evening, shooting up after the developer handily won an FDA expert panel vote backing the safety and efficacy of Xifaxan 550 mg tablets to treat hepatic encephalopathy. Story

> Switzerland's Basilea nailed a $510 million co-marketing pact with Astellas Pharma, hauling in a $70 million upfront payment and gaining a partner who will take over Phase III development of the late-stage antifungal isavuconazole, significantly reducing Basilea's burn rate. Report

> Shares of Millipore shot up at the beginning of the week on a whiff of rumors that the company is in play. Article

> Novelos (NVLT) announced this morning that its pivotal Phase III trial for its lead product--NOV-002--failed to hit the primary endpoint. Story

And Finally... New York University researchers found that elevated levels of a damaged protein may be an early sign of Alzheimer's disease. Report